Pharma: Page 40
-
Permission granted by Alloy.
ProfileFrom media to menopause: Creating new spaces in women's telehealth
Why the former editor-in-chief of Marie Claire abandoned her magazine career to create a menopause-focused women's health startup.
By Alexandra Pecci • March 29, 2022 -
Permission granted by Steve Leber.
How a rock 'n' roll guru is putting a new spin on health education for patients
A former agent for The Rolling Stones has launched a healthcare streaming platform with a cast of entertainment heavyweights — and he wants pharma to be a headline act.
By Meagan Parrish • March 28, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Stock via Getty Images
Q&ARare Patient Voice's president is striving to create a five-star experience for patients
Successful clinical trial recruitment depends on listening to and empowering patients.
By Kim Ribbink • March 23, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Merck's Dr. Mary-Ann Etiebet
The associate VP of health equity is on a quest to address the relationship between health, gender and economic opportunities.
By Taren Grom • March 23, 2022 -
Stock via Getty Images
Another pandemic threat looms, and the antibacterial drug pipeline still isn't keeping up
A recent report from BIO details challenges in the antibiotic market — and new policy measures that could help.
By Kelly Bilodeau • March 23, 2022 -
Stock via Getty Images
Q&AWhy Astellas is adopting a 'focus area approach' to partnerships
Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.
By Kim Ribbink • March 22, 2022 -
Stock via Getty Images
Psychedelics without the party: Inside MindMed's LSD makeover
MindMed’s CEO, Robert Barrow, on the company’s latest moves to ‘change the world’ with psychedelics.
By Alexandra Pecci • March 21, 2022 -
Retrieved from PharmaVOICE on March 21, 2022
Q&ABioMarin’s new global head of advocacy is tackling the holy grail of patient engagement
In her new role, Dr. Roz is keeping her patient-first approach.
By Taren Grom • March 21, 2022 -
Permission granted by Anthony Mack.
Virpax's CEO on leveraging new formulations to move drugs toward approval
Anthony Mack shares his lessons from getting unconventional pharma products across the finish line.
By Meagan Parrish • March 18, 2022 -
Stock via Getty Images
Civica Rx thinks it has a cure for high insulin prices
Civica’s president and CEO, Martin VanTrieste, explains the nonprofit’s aim to manufacture low-cost insulin — and which area of pharma it plans to target next.
By Kelly Bilodeau • March 16, 2022 -
Novartis' manufacturing facility for innovative cell and gene therapies in Stein, Switzerland. Permission granted by Novartis.
Q&AHow Novartis kept its supply chain intact during COVID-19
In an agile pivot, Amit Nastik led Novartis’ manufacturing operations through the pandemic without losing supply chain reliability.
By Taren Grom • March 16, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Ceek Women's Health CEO Fahti Khosrowshahi
Fahti Khosrowshahi, CEO and founder, Ceek Women’s Health, is designing award-winning products to change the face of women's health.
By Taren Grom • March 16, 2022 -
Stock via Getty Images
COVID-19 trials aren't the only studies that can achieve super speed
Is it possible to enroll clinical trials 10 times faster than the industry’s average speed? Elligo Health Research thinks so.
By Kelly Bilodeau • March 15, 2022 -
Image courtesy of Medigene.
Q&AMedigene's CEO on striking a collaboration deal with BioNTech
The two companies recently announced a $29 million collaboration.
By Jared Whitlock • March 15, 2022 -
Permission granted by Sanjeev Luther.
Q&AClearing hurdles in rare cancer drug development
Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.
By Kim Ribbink • March 14, 2022 -
Stock via Getty Images
Q&A // Biotech SpotlightLiquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage
The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.
By Taren Grom • March 14, 2022 -
Permission granted by Terry Weber
Q&ABiote CEO: Employers need to normalize women's health issues in the workforce
A survey by Biote reveals the impact of menopause on working women.
By Robin Robinson • March 14, 2022 -
Image courtesy of Ultragenyx.
Q&AUltragenyx's CEO on building a 'next-gen' rare disease company
How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.
By Kim Ribbink • March 9, 2022 -
Permission granted by Russell Potterfield.
ProfileFrom angel to operator: The unlikely journey of Endevica Bio's CEO
Russell Potterfield is honing his new found passion for the space to guide Endevica into the clinic.
By Jared Whitlock • March 9, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Genentech's Quita Highsmith
Quita Highsmith is changing how Genentech approaches diversity and inclusion across the board — from drug development to career advancement.
By Taren Grom • March 9, 2022 -
Stock via Getty Images
ProfileHorizon’s VP of R&D on her ascent in biotech — and bringing other female scientists along for the ride
Elizabeth Thompson is guiding Horizon through new drug approvals while leading the way for young women in STEM.
By Alexandra Pecci • March 8, 2022 -
Permission granted by Ramona Sequeira.
Q&ARamona Sequeira breaks PhRMA's glass ceiling
A few weeks ago, PhRMA, the industry’s largest trade group, announced that Sequeira has officially become chair of the organization’s board of directors. She is the first woman — and first woman of color — to take on the job.
By Taren Grom • March 7, 2022 -
Stock via Getty Images
Two key factors behind NYC's record-setting rise in healthcare funding
According to a new report, women’s and digital health led to an explosion in funding last year in NYC.
By Robin Robinson • March 7, 2022 -
Adobe Stock / peshkov
Sponsored by EVERSANASucceed when others fail: Avoiding 20% in investment waste during launch
Approximately 20% of pharma spend during launch is wasted. You can right-size spending during launch & across the lifecycle.
March 7, 2022 -
Stock via Getty Images
Are patients happy? This simple question could shake up clinical trials
The migration to DCTs is helping uncover critical gaps in patient experience.
By Kelly Bilodeau • March 4, 2022
Previous
